688085.SHG Shanghai Sanyou Medical Co Ltd
- Market cap
- CNY 4.69B
- P/E
- 98.4x
- P/B
- 2.10x
- ROE
- 3.0%
- Dividend yield
- 0.05%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688085.SHG undervalued?
Graham numberThe Graham number of Shanghai Sanyou Medical Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Sanyou Medical Co Ltd fundamental analysis
No fundamental analysis for Shanghai Sanyou Medical Co Ltd yet.
Shanghai Sanyou Medical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Sanyou Medical Co Ltd
Shanghai Sanyou Medical Co., Ltd. researches, develops, manufactures, and sells orthopedics implants in China. It is also involved in production of ultrasonic power equipment and consumables. The company offers spinal and trauma implants under Tytus and Sanyou brand. Its spinal products comprise anterior cervical plate, anterior thoracolumbar, posterior cervical, posterior thoracolumbar, and minimally invasive products; and shoulder and elbow system, hip and pelvis system, k…
Full company profileShanghai Sanyou Medical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Sanyou Medical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 75.3M | 140M | 222M | 354M | 390M | 593M | 649M | 460M | 454M | 543M | 587M |
| Gross Profit | 56.7M | 106M | 194M | 319M | 350M | 530M | 578M | 357M | 308M | 543M | 442M |
| Operating Income | 1.13M | 8.23M | 68.4M | 109M | 130M | 204M | 229M | 120M | 21.1M | 51.8M | 85.7M |
| EBITDA | 15.3M | 14.5M | 77.5M | 120M | 147M | 231M | 255M | 161M | 54.7M | 86.3M | 55.7M |
| Net Income | 3.13M | 5.20M | 62.1M | 97.8M | 119M | 186M | 191M | 95.6M | 11.5M | 63.3M | 63.2M |
| EPS | 0.01 | 0.03 | 0.28 | 0.44 | 0.43 | 0.63 | 0.64 | 0.32 | 0.04 | 0.19 | 0.17 |
| Balance Sheet | |||||||||||
| Total Assets | 178M | 336M | 389M | 551M | 1.67B | 2.00B | 2.19B | 2.26B | 2.31B | 2.38B | 2.39B |
| Total Liabilities | 19.6M | 46.8M | 48.3M | 114M | 136M | 261M | 278M | 219M | 258M | 252M | 286M |
| Shareholders' Equity | 158M | 289M | 340M | 438M | 1.53B | 1.69B | 1.84B | 1.92B | 1.91B | 2.10B | 2.10B |
| Cash & Short-term Investments | 54.2M | 34.4M | 25.7M | 37.5M | 1.14B | 759M | 534M | 674M | 453M | 336M | 300M |
| Total Debt | - | - | - | - | 3.45M | 5.07M | 5.39M | 4.99M | 31.6M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 19.4M | 21.5M | 19.8M | 61.7M | 77.5M | 145M | 156M | 267M | 11.0M | 68.0M | - |
| Capital Expenditure | 3.28M | 36.6M | 60.6M | 79.7M | 30.5M | 91.7M | 138M | 25.9M | 37.4M | 28.9M | 33.6M |
| Free Cash Flow | 16.1M | -15.1M | -40.8M | -18.0M | 47.1M | 53.3M | 17.8M | 241M | -26.5M | 39.1M | 2.27M |
| Ratios | |||||||||||
| ROE | 2.0% | 1.8% | 18.3% | 22.3% | 7.7% | 11.1% | 10.4% | 5.0% | 0.6% | 3.0% | 3.0% |
| ROA | 1.8% | 1.5% | 16.0% | 17.7% | 7.1% | 9.3% | 8.7% | 4.2% | 0.5% | 2.7% | 2.6% |
| Net Profit Margin | 4.2% | 3.7% | 28.0% | 27.6% | 30.4% | 31.4% | 29.4% | 20.8% | 2.5% | 11.7% | 10.8% |
| Debt to Equity | - | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai Sanyou Medical Co Ltd dividends
- Dividend yield
- 0.05%
- Forward dividend
- 0.02 CNY
- Payout ratio
- 3.4%
- Ex-dividend date
- Jun 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 2.14M | 0.01 | 3.4% |
| 2024 | CNY 22.7M | 0.08 | 197.5% |
| 2023 | CNY 19.2M | 0.06 | 20.1% |
| 2022 | CNY 37.4M | 0.13 | 19.6% |
| 2021 | CNY 35.7M | 0.12 | 19.2% |
| 2020 | CNY 35.9M | 0.13 | 30.2% |
| 2019 | CNY 35.9M | 0.16 | 36.7% |
| 2018 | CNY 10.8M | 0.05 | 17.3% |
| 2017 | CNY 10.8M | 0.06 | 207.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.1:1 on Jun 11, 2026.
Who owns Shanghai Sanyou Medical Co Ltd
- Insiders 39.51%
- Institutions 11.50%
- Public & others 48.99%
- Shares outstanding 367M
- Free float 226M
Shanghai Sanyou Medical Co Ltd company profile
- Company name
- Shanghai Sanyou Medical Co Ltd
- Ticker
- 688085.SHG
- ISIN
- CNE1000040J7
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 539
- Fiscal year end
- December
- Address
- Jiading Industrial Zone, Shanghai, China, 201815
- Phone
- 86 21 5826 6088
- Website
- sanyoumed.com
About Shanghai Sanyou Medical Co Ltd
Shanghai Sanyou Medical Co., Ltd. researches, develops, manufactures, and sells orthopedics implants in China. It is also involved in production of ultrasonic power equipment and consumables. The company offers spinal and trauma implants under Tytus and Sanyou brand. Its spinal products comprise anterior cervical plate, anterior thoracolumbar, posterior cervical, posterior thoracolumbar, and minimally invasive products; and shoulder and elbow system, hip and pelvis system, knee joint system, foot and ankle, and palm and wrist systems. In addition, the company offers spinal implant, trauma implant consumables, ultrasonic power system products, and vertebral body shaping consumables. Further, it provides sports medicine and surgical equipment. Shanghai Sanyou Medical Co., Ltd. was founded in 2005 and is based in Shanghai, China.
Shanghai Sanyou Medical Co Ltd management
5- Dr. Mingyan LiuChairman & Chief Scientist · born 1957
- Mr. Nong XuPresident, GM & Director · born 1964
- Ms. Nuan NiCFO & Accounting Supervisor · born 1981
- Ms. Xiaoyi ZhengSenior VP, COO & Director · born 1982
- Mr. Xianglong FanSenior VP, Deputy GM, Board Secretary & Director · born 1969